Sign inJoin waitlistJoin the waitlist

Tina Cascone

Associate Professor · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2014–2017
Internal Medicine
Washington University School of Medicine
2012–2013
University of Texas M D Anderson Cancer Center
2007–2012
University of Campania Luigi Vanvitelli
2004–2008
Doctor of Medicine
2000–2004

Research

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Cancer Discovery · 2016 · 1,305 citations
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Nature Medicine · 2021 · First of 53 authors · Corresponding · 558 citations
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
Cell Metabolism · 2018 · First of 37 authors · 503 citations

John Heymach
91 papers
Don Gibbons
57 papers
BS
Boris Sepesi
53 papers
Jianjun Zhang
49 papers
Ara Vaporciyan
41 papers
Stephen Swisher
37 papers
Annikka Weissferdt
31 papers
Xiuning Le
30 papers
JL
Joanna Lee
27 papers · 1 as a resident
Marcelo Negrao
24 papers
Lauren Byers
23 papers · 2 as a fellow
Mehmet Altan
23 papers

Grants

Dissecting the Role of B Lineage Cells in Mediating Response of Resectable Lung Cancer to Neoadjuvant Immune-Based Therapy
National Cancer Institute · R01
Contact PI · $2M · University of Tx Md Anderson Can Ctr
2024–2029
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer
National Cancer Institute · R01
PI · $3.2M · University of Tx Md Anderson Can Ctr
2021–2027

Clinical trials

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Principal investigator · Recruiting · Phase 2
AstraZeneca
2022–2030
Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2020–2021
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2017–2024
Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2015–2024